22. May 2024 | Corporate News

Marinomed Biotech AG announces results for the first quarter of 2024

  • Revenues for the first quarter 2024 declined to pre-pandemic levels of EUR 0.7 million driven by high customer stock levels and return of seasonality
  • Q1 2024: New partnerships for Carragelose and Solv4U, agreement with financing partners for deferral of repayments and progress with P&G for the U.S.
  • Several initiatives for both Marinosolv and Carragelose assets to generate sufficient cash flows covering the Company’s financing needs

The press release is available as download here:

Marinomed Biotech AG announces results for the first quarter of 2024
(88 KB)